Zevra Therapeutics reports positive pediatric data
Zevra Therapeutics (NASDAQ:ZVRA) reported positive data for MIPLYFFA (arimoclomol) from a phase 2/3 open-label pediatric substudy in infants with Niemann-Pick disease type C.
Zevra Therapeutics (NASDAQ:ZVRA) reported positive data for MIPLYFFA (arimoclomol) from a phase 2/3 open-label pediatric substudy in infants with Niemann-Pick disease type C.
Shopify (NYSE:SHOP) plans to ban all vape product sales from its e-commerce platform as early as this week, following pressure from U.S. state attorneys general.
Oracle (NYSE:ORCL) cut about 21,000 full-time jobs over the past year while accelerating its investment in AI data center infrastructure.
Meta (NASDAQ:META) launched a new line of AI-powered smart glasses called Meta Glasses, priced from $299 and designed in-house while still working in partnership with EssilorLuxottica.
Trinity Biotech (NASDAQ:TRIB) launched Trinovium, a subsidiary dedicated to advanced liquid cooling fluids and intelligence systems for AI and high-performance computing data centers.
Micron Technology (NASDAQ:MU) announced a strategic agreement with Anthropic that includes a memory and storage supply deal, technical collaboration on AI infrastructure, and a strategic investment in Anthropic’s Series H funding round.
Revolution Medicines (NASDAQ:RVMD) began dosing patients in its global Phase 3 RASolute 305 trial for metastatic pancreatic cancer.
President Donald Trump announced that Iran has agreed to reinstate nuclear inspections by the International Atomic Energy Agency (IAEA), a development that sent ripples through global markets.
Allergan Aesthetics (NYSE:ABBV) received Health Canada approval for Boey (trenibotulinumtoxinE) to temporarily improve the appearance of moderate to severe glabellar (frown) lines in adults.
GET YOUR GRAFA EDGE NOW
We'll switch on a 30-day Edge trial as a welcome gift
Got a second for a cookie? 🍪Essential cookies keep Grafa running smoothly. A few optional ones help us see what's working so we can make it better. You're in control — change your mind any time. Cookie policy · Privacy policy